Stocks and Investing
Stocks and Investing
Thu, October 22, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Peter Lawson Upgraded (AGIO) to Buy and Held Target at $46 on, Oct 22nd, 2020
Peter Lawson of Barclays, Upgraded "Agios Pharmaceuticals, Inc." (AGIO) to Buy and Held Target at $46 on, Oct 22nd, 2020.
Peter has made no other calls on AGIO in the last 4 months.
There are 3 other peers that have a rating on AGIO. Out of the 3 peers that are also analyzing AGIO, 0 agree with Peter's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Peter
- Andrew Berens of "SVB Leerink" Maintained at Buy with Decreased Target to $67 on, Monday, October 19th, 2020
- John Newman of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $70 on, Monday, October 19th, 2020
- Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $72 on, Friday, July 31st, 2020
Contributing Sources